Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949336 | 0.82 | RXRA (0.42) | CA2RAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL3081383 | 0.81 | CYP2A6 (0.46) | AGXTCA1CA2CA9RAB9A | |
| SCHEMBL3092949 | 0.79 | IDO1 (0.50) | CA2IDO1ALDH1A1TAAR1 | |
| SCHEMBL6341 | 0.78 | IDO1 (0.55) | AGXTCA1CA2CA9RAB9A | |
| SCHEMBL9258996 | 0.78 | CA2 (0.42) | CA2RAB9ANPC1ALDH1A1MAPT | |
| SCHEMBL8480 | 0.77 | IDO1 (0.52) | CA1CA2CA9MAOBIDO1 | |
| SCHEMBL8816 | 0.77 | IDO1 (0.52) | AGXTCA1CA2CA9MAOB | |
| SCHEMBL177563 | 0.77 | ALDH1A1 (0.44) | CA2CA9RAB9AMAOBALDH1A1 | |
| SCHEMBL513966 | 0.77 | CYP3A4 (0.52) | IDO1 | |
| SCHEMBL95538 | 0.77 | IDO1 (0.52) | AGXTCA1CA2CA9MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 685 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396296-A | Preparation method of ertapenem | 武汉瑞晟药业有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-10322995-B2 | Substituted cyano cycloalkyl penta-2,4-dienes, cyano cycloalkyl pent-2-en-4-ynes, cyano heterocyclyl penta-2,4-dienes and cyano heterocyclyl pent-2-en-4-ynes as active substances against abiotic plant stress | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2019-06-18 | — | — | US | claimed |
| EP-1412078-B1 | PROCESSES FOR THE PRODUCTION OF AMINO-PROTECTED DERIVATIVES OF 4-AMINOMETHYLENE-PYRROLIDIN-3-ONE, GEMIFLOXACIN OR A SALT THEREOF | LG LIFE SCIENCES LTD (KR) | 2008-10-08 | — | — | EP | claimed |
| US-20070161634-A1 | Compounds as CCR5 antagonists | SHANGHAI TARGET DRUG CO., LTD. (CN) | 2007-07-12 | — | — | US | claimed |
| US-7199242-B2 | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof | LG LIFE SCIENCES LIMITED (KR) | 2007-04-03 | — | — | US | claimed |
| US-7192983-B2 | Improving storage stability by reacting with hydrogen sulfate lithium- containing compound; aspartyl protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-20 | — | — | US | claimed |
| EP-1760079-A1 | COMPOUNDS AS COR5 ANTAGONISTS | Shanghai Target Drug Co., Ltd. (CN) | 2007-03-07 | — | — | EP | claimed |
| US-20060074247-A1 | N-protected/N-substituted-beta-amino hydroxy sulfonates | G.D. SEARLE & CO. (US) | 2006-04-06 | — | — | US | claimed |
| EP-1134222-B1 | IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM | SHIONOGI & CO (JP) | 2005-04-13 | — | — | EP | claimed |
| US-20050043546-A1 | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof | LG CHEM, LTD. (KR) | 2005-02-24 | — | — | US | claimed |
| EP-0342649-A2 | Improved process for the preparation of 5-amino-7-(substituted amino)-quinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1989-11-23 | — | — | EP | claimed |
| US-4788185-A | Cephalosporin compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-29 | — | — | US | claimed |
| EP-0111421-B1 | OXACEPHALOSPORIN DERIVATIVES, THEIR PREPARATION AND USE | SHIONOGI & CO., LTD. (JP) | 1986-08-20 | — | — | EP | claimed |
| US-4581170-A | N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones | E. R. SQUIBB & SONS, INC. (US) | 1986-04-08 | — | — | US | claimed |
| EP-0170280-A1 | Novel intermediates and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones | E.R. Squibb & Sons, Inc. (US) | 1986-02-05 | — | — | EP | claimed |
| US-4532233-A | Antibiotics | SHIONOGI & CO., LTD. (JP) | 1985-07-30 | — | — | US | claimed |
| US-4529722-A | A 7-ureidoacetamido-7a-methoxy-3-(1-(2-hydroxyethyl)-1H-tetrazol-5 -yl)thiomethyl-1-dethia-1-oxa-3-cephem carboxylic acid derivative | SHIONOGI & CO., LTD. (JP) | 1985-07-16 | — | — | US | claimed |
| EP-0111421-A1 | Oxacephalosporin derivatives, their preparation and use | SHIONOGI & CO., LTD. (JP) | 1984-06-20 | — | — | EP | claimed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | claimed |
| US-4180571-A | Arylmalonamido-1-oxadethiacephalosporins | SHIONOGI & CO., LTD. (JP) | 1979-12-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043546-A1 | Processes for the production of amino-protected derivatives of 4-aminomethylene-pyrrolidin-3-one and/or 4-aminomethylene-pyrrolidin-3-alkoxyimino derivatives and/or gemifloxacin or a salt thereof | CYP4X1, PM20D2, BRIX1 | AGXT 6/4885CA1 2501/4885CA2 1057/4885 |
| US-20070161634-A1 | Compounds as CCR5 antagonists | CCR5, CXCR3, CCL5 | AGXT 3387/4885CA1 4310/4885CA2 3718/4885 |
| US-20060074247-A1 | N-protected/N-substituted-beta-amino hydroxy sulfonates | AANAT, AASDHPPT, ALDH7A1 | AGXT 413/4885CA1 2109/4885CA2 3093/4885 |
| US-10322995-B2 | Substituted cyano cycloalkyl penta-2,4-dienes, cyano cycloalkyl pent-2-en-4-ynes, cyano heterocyclyl penta-2,4-dienes and cyano heterocyclyl pent-2-en-4-ynes as active substances against abiotic plant stress | NPY2R, NPY1R, XPA | AGXT 261/4885CA1 2667/4885CA2 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.